TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer&Amp;#39;s Disease

Phosphorylated Tau Levels in Donated Blood

Eligible age

All ages

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.

Sponsor: The University of Texas Health Science Center, Houston

You may qualify if…

  • ✓ The plasma sample from donators.

You may not qualify if…

  • ✕ None.

Where it's recruiting

Texas

Houston

Source: ClinicalTrials.gov · NCT07157839 · last updated 2026-02-11

Phosphorylated Tau Levels in Donated Blood · TrialPath